Trial · NCT00749723
Therapy Optimization Trial for the Treatment of Relapsed or Refractory Brain Tumors in Children
NCT00749723, Phase 2, Phase 3, Completed, University Hospital, Bonn
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Therapy Optimization Trial for the Treatment of Relapsed or Refractory Brain Tumors in Children. Trials, record NCT00749723. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00749723
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Therapy Optimization Trial for the Treatment of Relapsed or Refractory Brain Tumors in Children
- NCT number
- NCT00749723
- Status
- Completed
- Phases
- Phase 2, Phase 3
- Enrollment
- 174 participants, actual
- Lead sponsor
- University Hospital, Bonn
- Conditions
- Recurrent Brain Tumors, Supratentorial PNETs, Medulloblastomas, Ependymomas
- Interventions
- carboplatin, etoposide, temozolomide, thiotepa, carboplatin, etoposide, temozolomide, thiotepa, autologous stem cell transplantation, intraventricular etoposide, trofosfamide, etoposide
- First posted
- 2008-09-09
- Last updated
- 2018-07-20
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | P-HIT-REZ 2005 study: two Chemotherapy-arms: response evaluation after the fourth therapy course | 4 months for each patient (8 years for the whole study population) | determination of objective repsonse rate (CR+PR) |
| Primary | E-HIT-REZ 2005 study (Phase II Study "Oral chemotherapy with temozolomide"): Evaluation of response rate to the 60-days oral chemotherapy with temozolomide | 2 months for each patient (8 years for the whole study population) | determination of objective repsonse rate (CR+PR/all patients) |
| Primary | Phase II study "Intraventricular therapy with etoposide": Evaluation of response rate to the 5-week intraventricular therapy with etoposide | 6 weeks for each patient (8 years for the whole study population) | disease stabilization rate (CR+PR+SD/all patients) |
| Secondary | P-HIT-REZ 2005 study: two Chemotherapy-arms: PFS and OS from start of therapy | 10 years | progression free and overall survival from start of therapy until PD, last follow up or death, respectively |
| Secondary | P-HIT-REZ 2005 study: two Chemotherapy-arms: toxicity rate (CTC) in both arms | 8 years | rate of adverse events of CTC°3 or CTC°4 according to CTCAE v3.0 |
| Secondary | E-HIT-REZ 2005 study: Chemotherapy-arm: PFS and OS from start of therapy | 10 years | progression free and overall survival from start of therapy until PD, last follow up or death, respectively |
| Secondary | E-HIT-REZ 2005 study: Chemotherapy-arm: toxicity rate (CTC) | 10 years | progression free and overall survival from start of therapy until PD, last follow up or death, respectively |
| Secondary | Phase II study "Intraventricular therapy with etoposide": toxicity rate (CTC) | 8 years | rate of adverse events of CTC°1-4 according to CTCAE v3.0 |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00749723
GET https://conductscience.org/api/trials/v1/NCT00749723/registered